Angiodynamics Inc (ANGO) Hedge Fund & Institutional Holdings (Q2 2026)

ANGO ranks #3514 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ANGO is a disclosed holding of Steve Cohen (Point72 Asset Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

ANGO is a top-conviction position for Broadfin Holdings LLC — at 100.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ANGO belongs to BlackRock, Inc., but the position matters far more to Broadfin Holdings LLC, who has 100.0% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Atria Investments, Inc has added to its ANGO position for two straight quarters, increasing it by $222.4K to reach $743.5K today.

ANGO is down 2.9% today, but institutions show net buying of $7.1M this quarter — a divergence between today's price move and the underlying institutional flow.

ANGO reported a net loss of $36.7M over the trailing twelve months.

• Not yet profitable — net loss of $36.7M over the trailing twelve months
• Revenue grew 9.5% year over year
• Net income declined year over year, from -$34.0M to -$36.7M
• Generated $3.1M in positive operating cash flow
• Current ratio of 2.19x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.56x equity — within a conventional range